A Single-Arm, Multicenter, Phase II Study of Camrelizumab in Relapsed or Refractory Classical Hodgkin Lymphoma

Song, Yuqin; Wu, Jianqiu; Chen, Xinchuan; Lin, Tongyu; Cao, Junning; Liu, Yanyan; Zhao, Yaozhong; Jin, Jie; Huang, Haiwen; Hu, Jianda; Luo, Jie; Zhang, Liling; Hou, Xue; Zhang, Qingyuan; Wang, Weiwei; Chen, Chun Xia; Feng, Jifeng; Zhu, Jun

doi:10.1158/1078-0432.ccr-19-1680

Cited by 125 publications

(111 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1). Twenty-seven of them were excluded as they were conference abstracts, leaving 13 eligible studies consisting of 1063 patients for analysis [20][21][22][23][24][25][26][27][28][29][30][31][32] . Basic information of these studies were shown in Table 1.…”

Section: Resultsmentioning

confidence: 99%

Landscape of immune checkpoint inhibitor-related adverse events in Chinese population

Rao

et al. 2020

Sci Rep

View full text Add to dashboard Cite

This study aimed to describe the landscape of Immune checkpoint inhibitors (ICIs)-related adverse events (AEs) in a predominantly Chinese cohort. We searched electronic datasets including PubMed, Web of Science and Embase to identify and recruit relevant trials up to September 2, 2019. Clinical trials focusing on ICIs in Chinese patients or a predominantly Chinese population were included. Incidences of treatment-related AEs (TRAEs) and immune-related AEs (irAEs) were pooled and compared. In total, we recruited 13 trials consisting of 1063 patients, with 922 (86.7%) receiving ICI monotherapy and 141 (13.3%) receiving combination of ICI with chemotherapy or anti-angiogenesis. The pooled incidence of any grade TRAEs, grade 1–2, grade 3–5 TRAEs, any grade irAEs, grade 1–2 irAEs and grade 3–5 irAEs in all 1063 patients were 84.1%, 63.3%, 20.9%, 43.3%, 40.0% and 3.0%, respectively. Moreover, 4.3% (44/1018) of patients experienced treatment discontinuation and only 8 (0.8%) patients experienced treatment-related death. Compared to ICI monotherapy, combination significantly increased grade 3–5 TRAEs (46.1% vs. 17.0%, P < 0.001) and grade 3–5 irAEs (7.1% vs. 2.0%, P = 0.015). By comparing the toxicity profiles between different ICIs, we found some drug-specific AEs such as reactive capillary haemangiomas for camrelizumab (58.6%), hyperglycemia for toripalimab (55.6%) and pyrexia for tislelizumab (54.3%). Additionally, nivolumab has the lowest incidence of any grade (64.1%) and grade 3–5 (11.8%) TRAEs. ICI-related AEs were generally mild and tolerable for a predominantly Chinese cohort. However, we should pay attention to the combination of ICI with chemotherapy as it could increase grade 3–5 TRAEs and irAEs.

show abstract

Section: Resultsmentioning

confidence: 99%

Landscape of immune checkpoint inhibitor-related adverse events in Chinese population

Rao

et al. 2020

Sci Rep

View full text Add to dashboard Cite

show abstract

“…They have demonstrated similar anti-cancer activities as those developed in the USA although some of them demonstrated higher in vitro binding affinity to the PD-1. Three of them have been approved for treating classical Hodgkin's lymphoma whereas one has been approved for treating melanoma [34][35][36][37][38][39][40]. None of them have been approved for more common types of malignancies such as NSCLC.…”

Section: Simple Addition: the Traditional Methods Of Combination Ici Dmentioning

confidence: 99%

Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy

et al. 2020

View full text Add to dashboard Cite

Cancer immunotherapy has reached a critical point, now that immune checkpoint inhibitors and two CART products have received market approval in treating 16 types of cancers and 1 tissue-agnostic cancer indication. Accompanying these advances, the 2018 Nobel Prize was awarded for the discovery of immune checkpoint pathways, which has led to the revolution of anti-cancer treatments. However, expanding the indications of immuno-oncology agents and overcoming treatment resistance face mounting challenges. Although combination immunotherapy is an obvious strategy to pursue, the fact that there have been more failures than successes in this effort has served as a wake-up call, placing emphasis on the importance of building a solid scientific foundation for the development of next-generation immuno-oncology (IO) agents. The 2019 China Cancer Immunotherapy Workshop was held to discuss the current challenges and opportunities in IO. At this conference, emerging concepts and strategies for IO development were proposed, focusing squarely on correcting the immunological defects in the tumor microenvironment. New targets such as Siglec-15 and new directions including neoantigens, cancer vaccines, oncolytic viruses, and cytokines were reviewed. Emerging immunotherapies were discussed in the areas of overcoming primary and secondary resistance to existing immune checkpoint inhibitors, activating effector cells, and targeting immunosuppressive mechanisms in the tumor microenvironment. In this article, we highlight old and new waves of IO therapy development, and provide perspectives on the latest momentum shifts in cancer immunotherapy.

show abstract

“…For example, for patients with relapsed or refractory classical Hodgkin lymphoma, tislelizumab (anti-PD-1) achieved an objective response rate of 87.1% and a complete response of 62.9%, in a phase II, single-arm, multicenter study [7]. Similarly, the complete response rate of camrelizumab (anti-PD-1) was 28.0%, with a partial remission rate of 48.0% [29].…”

Section: Resistance To Pd-1/pd-l1 Blockade Therapymentioning

confidence: 99%

Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives

et al. 2020

View full text Add to dashboard Cite

PD-1/PD-L1 blockade therapy is a promising cancer treatment strategy, which has revolutionized the treatment landscape of malignancies. Over the last decade, PD-1/PD-L1 blockade therapy has been trialed in a broad range of malignancies and achieved clinical success. Despite the potentially cure-like survival benefit, only a minority of patients are estimated to experience a positive response to PD-1/PD-L1 blockade therapy, and the primary or acquired resistance might eventually lead to cancer progression in patients with clinical responses. Accordingly, the resistance to PD-1/PD-L1 blockade remains a significant challenge hindering its further application. To overcome the limitation in therapy resistance, substantial effort has been made to improve or develop novel anti-PD-1/PD-L1 based immunotherapy strategies with better clinical response and reduced immune-mediated toxicity. In this review, we provide an overview on the resistance to PD-1/PD-L1 blockade and briefly introduce the mechanisms underlying therapy resistance. Moreover, we summarize potential predictive factors for the resistance to PD-1/PD-L1 blockade. Furthermore, we give an insight into the possible solutions to improve efficacy and clinical response. In the following research, combined efforts of basic researchers and clinicians are required to address the limitation of therapy resistance.

show abstract

A Single-Arm, Multicenter, Phase II Study of Camrelizumab in Relapsed or Refractory Classical Hodgkin Lymphoma

Cited by 125 publications

References 20 publications

Landscape of immune checkpoint inhibitor-related adverse events in Chinese population

Landscape of immune checkpoint inhibitor-related adverse events in Chinese population

Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy

Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives

Contact Info

Product

Resources

About